RU95108591A - METHOD FOR DETERMINING THE STATE OF SEPSIS DISEASE - Google Patents

METHOD FOR DETERMINING THE STATE OF SEPSIS DISEASE

Info

Publication number
RU95108591A
RU95108591A RU95108591/14A RU95108591A RU95108591A RU 95108591 A RU95108591 A RU 95108591A RU 95108591/14 A RU95108591/14 A RU 95108591/14A RU 95108591 A RU95108591 A RU 95108591A RU 95108591 A RU95108591 A RU 95108591A
Authority
RU
Russia
Prior art keywords
procalcitonin
monoclonal antibody
peptide
antibody
sepsis
Prior art date
Application number
RU95108591/14A
Other languages
Russian (ru)
Other versions
RU2137130C1 (en
Inventor
Бохуон Клод
Original Assignee
Хеннинг Берлин ГмбХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4227454A external-priority patent/DE4227454C1/en
Application filed by Хеннинг Берлин ГмбХ filed Critical Хеннинг Берлин ГмбХ
Publication of RU95108591A publication Critical patent/RU95108591A/en
Application granted granted Critical
Publication of RU2137130C1 publication Critical patent/RU2137130C1/en

Links

Claims (14)

1. Способ раннего выявления, выявления тяжести и оценки курса лечения сепсиса, отличающийся тем, что в образце биологической жидкости пациента определяют содержание пептидного прокальцитонина и/или образующегося из него неполного пептида, который не является созревшим кальцитонином, причем определяемое присутствия и количество определенного пептида является показателем наличия сепсиса, его тяжести и/или успеха терапевтического лечения.1. A method for the early detection, severity and assessment of the course of treatment of sepsis, characterized in that the content of peptide procalcitonin and / or the incomplete peptide that is not matured calcitonin is determined in the patient’s biological fluid sample, and the determined presence and quantity of a particular peptide is an indicator of the presence of sepsis, its severity and / or success of therapeutic treatment. 2. Способ по п. 1, отличающийся тем. что определяют прокальцитонин и/или N-прокальцитонин-(1-57)-пептид и/или С-прокальцитонин-(60-116)- пептиды. 2. The method according to p. 1, characterized in that. that procalcitonin and / or N-procalcitonin- (1-57) -peptide and / or C-procalcitonin- (60-116) -peptides are determined. 3. Способ по п. 1 или 2, отличающийся тем, что при осуществлении иммунодиагностического способа обнаруживают соответствующий пептид или пептиды путем использования моноклонального антитела или комбинации первого моноклонального или поликлонального антитела с вторым моноклональным антителом, которые как таковые или в комбинации друг с другом обладают специфичностью прокальцитонина или образующихся из него пептидов и которые позволяют сделать дифференциацию между ними и зрелым кальцитонином и пептидом CGRP. 3. The method according to p. 1 or 2, characterized in that when implementing the immunodiagnostic method, the corresponding peptide or peptides are detected by using a monoclonal antibody or a combination of a first monoclonal or polyclonal antibody with a second monoclonal antibody, which as such or in combination with each other have specificity procalcitonin or peptides formed from it and which allow differentiation between them and mature calcitonin and the CGRP peptide. 4. Способ по п. 3, отличающийся тем. что прокальцитонин обнаруживают путем иммунометрического анализа, в котором для связывания прокальцитонина образца используется первое моноклональное антитело, связывающее прокальцитонин в другой области как второе моноклональное антитело, используемое для индикации, так что возможна дифференциация между прокальцитонином и продуктами его протеолитического разложения, включая кальцитонин. 4. The method according to p. 3, characterized in that. that procalcitonin is detected by immunometric analysis, in which the first monoclonal antibody that binds procalcitonin in another region is used as the second monoclonal antibody used to indicate the binding of procalcitonin to the sample, so that differentiation between procalcitonin and its proteolytic degradation products, including calcitonin, is possible. 5. Способ по п. 4, отличающийся тем, что не считая первого моноклонального антитела, для связывания прокальцитонина используется по меньшей мере одно дополнительное моноклональное антитело, которое связывает прокальцитониновую молекулу в другой, следующей области. 5. The method according to p. 4, characterized in that in addition to the first monoclonal antibody, at least one additional monoclonal antibody is used to bind procalcitonin, which binds the procalcitonin molecule in another, next region. 6. Способ по любому из пп. 3-5, отличающийся тем. что прокальцитонин обнаруживают путем иммунометрического анализа, который избирательно обнаруживает полный прокальцитонин и/или С-прокальцитонин-(60-116)-пептид. 6. The method according to any one of paragraphs. 3-5, characterized in that. that procalcitonin is detected by an immunometric assay that selectively detects total procalcitonin and / or C-procalcitonin- (60-116) -peptide. 7. Способ по любому из пп. 3-5, отличающийся тем, что прокальцитонин обнаруживают путем иммунометрического анализа, который избирательно обнаруживает полный прокальцитонин и/или N-прокальцитонин-(1-57)-пептид. 7. The method according to any one of paragraphs. 3-5, characterized in that procalcitonin is detected by immunometric analysis, which selectively detects the full procalcitonin and / or N-procalcitonin- (1-57) -peptide. 8. Способ по п. 7, отличающийся тем, что содержания прокальцитонина более, чем 1 нг/мл образца являются показательными для возможного наличия сепсиса и тем, что содержания прокальцитонина в пределах от 10 нг/мл до 500 нг/мл и более связаны с увеличивающейся тяжестью сепсиса и ухудшенным прогнозом. 8. The method according to p. 7, characterized in that the content of procalcitonin more than 1 ng / ml of the sample are indicative of the possible presence of sepsis and the fact that the content of procalcitonin in the range from 10 ng / ml to 500 ng / ml or more are associated with increasing severity of sepsis and poor prognosis. 9. Способ по п. 8, отличающийся тем, что одновременно в параллельном анализе обнаруживают содержание кальцитонина и тем, что отсутствие доказательства повышенных содержаний кальцитонина позволяет поставить диагноз сепсиса. 9. The method according to p. 8, characterized in that at the same time in a parallel analysis detect the content of calcitonin and the fact that the lack of evidence of increased levels of calcitonin allows you to diagnose sepsis. 10. Способ по пп. 8 или 9, отличающийся тем, что содержания прокальцитонина в пределах примерно до 20 нг/мл позволяют поставить диагноз сепсиса, если может быть исключено наличие серьезных вирусных заболеваний, как причины повышенной концентрации прокальцитонина. 10. The method according to PP. 8 or 9, characterized in that the content of procalcitonin in the range of up to about 20 ng / ml makes it possible to diagnose sepsis, if serious viral diseases can be excluded, as the reasons for the increased concentration of procalcitonin. 11. Способ по любому из пп. 1-10, отличающийся тем, что образец сыворотки или плазмы используют как образец биологической жидкости. 11. The method according to any one of paragraphs. 1-10, characterized in that the serum or plasma sample is used as a sample of biological fluid. 12. Способ по любому из пп. 1-11, отличающийся тем, что моноклональное антитело представляет собой моноклональное антитело КС01 (DSM АСС2124) или антитело СТ21 (DSM АСС2125). 12. The method according to any one of paragraphs. 1-11, characterized in that the monoclonal antibody is a monoclonal antibody KC01 (DSM ACC2124) or antibody CT21 (DSM ACC2125). 13. Комплект средств для осуществления способа по любому из пп. 1-12, отличающийся тем, что для обнаружения прокальцитонина в количествах от 0,1 до 500 нг/мл образца сыворотки или плазмы данные средства включают одно (или множество) иммобилизированное (иммобилизированных) первое моноклональное или поликлональное антитело (или моноклональных или поликлональных антител) на носителе для связывания прокальцитонина образца; дополнительное моноклональное антитело, несущее маркер и связывающее прокальцитонин в области, которая отлична от связывающей области первого антитела (или первых антител); и общие вспомогательные средства. 13. A set of tools for implementing the method according to any one of paragraphs. 1-12, characterized in that for the detection of procalcitonin in amounts from 0.1 to 500 ng / ml of a serum or plasma sample, these agents include one (or many) immobilized (immobilized) first monoclonal or polyclonal antibodies (or monoclonal or polyclonal antibodies) on a carrier for binding procalcitonin to a sample; an additional monoclonal antibody carrying a marker and binding procalcitonin in a region that is different from the binding region of the first antibody (or first antibodies); and general aids. 14. Комплект средств по п. 13, в котором первое или дополнительное моноклональное антитело представляет собой антитело КС01 (DSM АСС2124) или антитело СТ21 (DSM АСС2125) соответственно. 14. The kit according to claim 13, in which the first or additional monoclonal antibody is an antibody KC01 (DSM ACC2124) or an antibody CT21 (DSM ACC2125), respectively.
RU95108591A 1992-08-19 1993-08-19 Method for early determining disease gravity and estimating sepsis treatment process and also means for implementing this method RU2137130C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4227454A DE4227454C1 (en) 1992-08-19 1992-08-19 Process for early detection, for the detection of the severity as well as for the therapy-accompanying assessment of the course of sepsis as well as means for carrying out the process
DEP4227454.0 1992-08-19
PCT/EP1993/002245 WO1994004927A1 (en) 1992-08-19 1993-08-19 Method for diagnosing and monitoring sepsis

Publications (2)

Publication Number Publication Date
RU95108591A true RU95108591A (en) 1997-11-27
RU2137130C1 RU2137130C1 (en) 1999-09-10

Family

ID=6465882

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95108591A RU2137130C1 (en) 1992-08-19 1993-08-19 Method for early determining disease gravity and estimating sepsis treatment process and also means for implementing this method

Country Status (18)

Country Link
US (1) US5639617A (en)
EP (1) EP0656121B1 (en)
JP (1) JP3257796B2 (en)
CN (1) CN1050668C (en)
AT (1) ATE163767T1 (en)
AU (1) AU686114B2 (en)
BR (1) BR9306928A (en)
CA (1) CA2142599C (en)
DE (2) DE4227454C1 (en)
ES (1) ES2114065T3 (en)
HR (1) HRP931147A2 (en)
IL (1) IL106698A0 (en)
MX (1) MX9305028A (en)
NO (1) NO950594L (en)
RU (1) RU2137130C1 (en)
SI (1) SI9300433A (en)
WO (1) WO1994004927A1 (en)
ZA (1) ZA936042B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600875C1 (en) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostic procedure for determining the etiology of inflammatory processes
US8932227B2 (en) * 2000-07-28 2015-01-13 Lawrence A. Lynn System and method for CO2 and oximetry integration
US5993811A (en) * 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
WO1999027482A1 (en) * 1997-11-20 1999-06-03 Beth Israel Deaconess Medical Center Neonatal illness severity/mortality computerized determination system & method
DE19847690A1 (en) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Diagnosing sepsis and severe infections, useful for assessing severity and progress of treatment, by measuring content of peptide prohormone or their derived fragments
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
DE19903336C2 (en) * 1999-01-28 2000-12-14 Brahms Diagnostica Gmbh Ready-to-use calibrators for the determination of procalcitonin
EP1110970B1 (en) 1999-12-22 2008-05-14 Dade Behring Marburg GmbH Anti-Procalcitonin antibodies, their production and use
ES2280170T3 (en) 1999-12-22 2007-09-16 Dade Behring Marburg Gmbh HUMAN PROCALCITONINE SOLUTIONS.
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US20040028651A1 (en) * 2001-03-29 2004-02-12 Karrupiah Muthumani Composition and methods of using hiv vpr
DE10119804A1 (en) * 2001-04-23 2002-10-24 Brahms Ag New peptides produced in primates during inflammation and sepsis, useful for diagnosis and treatment of these diseases, and their related antibodies
DE10130985B4 (en) * 2001-06-27 2004-03-18 B.R.A.H.M.S Ag Procedure for the diagnosis of sepsis and severe infections by determining soluble cytokeratin 1 fragments
DE10131922A1 (en) * 2001-07-02 2003-01-30 Brahms Ag Use of the Calcineurin B homologous protein (CHP) for the diagnosis and therapy of inflammatory diseases and sepsis
US6939716B2 (en) * 2001-09-19 2005-09-06 Washington University Method for detecting conditions indicative of sepsis
US20050042202A1 (en) * 2001-10-05 2005-02-24 Weiner David B. Compositions for and methods of treating and preventing sirs/sepsis
ATE309542T1 (en) * 2001-12-04 2005-11-15 Brahms Ag USE OF GLYCINE N-ACYL TRANSFERASE (GNAT) FOR THE DIAGNOSIS OF INFLAMMATORY DISEASES AND SEPSIS
EP1318403B1 (en) 2001-12-04 2004-07-28 B.R.A.H.M.S Aktiengesellschaft Diagnosis of sepsis determining S100B
ATE282831T1 (en) * 2001-12-04 2004-12-15 Brahms Ag METHOD FOR DIAGNOSIS OF SEPSIS USING SOLUBLE CYTOKERATIN FRAGMENTS
EP1318402B1 (en) * 2001-12-04 2005-04-20 B.R.A.H.M.S Aktiengesellschaft Diagnosis of sepsis determining CA 125
EP1318404B1 (en) * 2001-12-04 2004-07-28 B.R.A.H.M.S Aktiengesellschaft Diagnosis of sepsis determining CA 19-9
DE50103907D1 (en) * 2001-12-07 2004-11-04 Brahms Ag Uses of aldose-1-epimerase (mutarotase) for the diagnosis of inflammatory diseases and sepsis
US7465555B2 (en) * 2002-04-02 2008-12-16 Becton, Dickinson And Company Early detection of sepsis
EP1355158A1 (en) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Method for diagnosing inflammatory and infectious diseases by detecting the phosphoprotein LASP-1 as inflammation marker
EP1355159A1 (en) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Use of fragments of carbamyl phosphate synthetase I (CPS 1) for the diagnosis of inflammatory diseases and sepsis
EP1367395A1 (en) 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnosis of neoplasms with the help of anti-gangliosid-antibodies
EP1369693A1 (en) * 2002-06-04 2003-12-10 B.R.A.H.M.S Aktiengesellschaft Method for the diagnosis of sepsis and the control of donor blood with the help of anti-asialo ganglioside antibodies
EP1369118A1 (en) * 2002-06-04 2003-12-10 B.R.A.H.M.S Aktiengesellschaft Process and agent for the prevention, inhibition and therapy of sepsis
CA2491026A1 (en) * 2002-07-05 2004-01-15 The University Of British Columbia Diagnosis of sepsis using mitochondrial nucleic acid assays
CA2505843A1 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
MXPA05005031A (en) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnosis of sepsis or sirs using biomarker profiles.
MXPA05005073A (en) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnosis of sepsis or sirs using biomarker profiles.
DE10316583A1 (en) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Determination of a mid-regional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, as well as immunoassays for carrying out such a determination
KR100540659B1 (en) * 2003-07-02 2006-01-10 삼성전자주식회사 Method and apparatus for printing enlarged image, and computer-readable recording media for storing computer program
WO2005033327A2 (en) * 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
US20050170443A1 (en) * 2003-10-03 2005-08-04 Scantibodies Laboratory, Inc. Methods and use of binding components for improving assay specificity
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
EP1562046A1 (en) * 2004-02-03 2005-08-10 B.R.A.H.M.S Aktiengesellschaft Method of diagnosing sepsis by detecting selectively the concentration of superoxide dismutase 1 (SOD-1) in samples
US7659087B2 (en) * 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
DE102004045705A1 (en) 2004-09-21 2006-04-06 B.R.A.H.M.S Ag Uses of carbamoyl phosphate synthetase 1 (CPS) as a humoral biomarker for the diagnosis of tumors and inflammatory bowel disease
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20060157647A1 (en) * 2005-01-18 2006-07-20 Becton, Dickinson And Company Multidimensional liquid chromatography/spectrometry
DE102005003687A1 (en) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunodiagnostic determination of neurotensin in mammal blood, comprises injecting immune active N-terminal mammal proneurotensin in to the serum- or plasma- sample
CA2605143A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
DE102006046996A1 (en) 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnosis process for respiratory infections involves using procalcitonin as marker for assessing patient risk level
DE102006053442A1 (en) 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnosis and risk stratification of infections and chronic diseases of the respiratory and lungs by means of proVasopressin, in particular copeptin or neurophysin II
DE102007009751A1 (en) * 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Diagnostic immunoassay for procalcitonin in a biological sample from a patient comprises selectively determining full-length procalcitonin 1-116
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8097424B2 (en) * 2007-05-29 2012-01-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for predicting the outcome of a critically ill patient
EP2020603A1 (en) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Method for risk stratification in stable coronary artery disease
ES2377112T3 (en) 2007-08-03 2012-03-22 B.R.A.H.M.S Gmbh Method for the diagnosis of a bacterial infection
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
JP5474937B2 (en) 2008-05-07 2014-04-16 ローレンス エー． リン， Medical disorder pattern search engine
EP2376923A4 (en) * 2008-12-22 2012-08-15 Children S Res Inst Methods for detection of sepsis
WO2010125076A1 (en) * 2009-04-28 2010-11-04 B.R.A.H.M.S Aktiengesellschaft Immunoassay for the detection of procalcitonin
WO2011127176A2 (en) * 2010-04-06 2011-10-13 The Children's Research Institute Methods for treating or screening for compounds for the treatment of sepsis
CN103119444B (en) 2010-04-21 2016-10-26 米密德诊断学有限公司 Distinguish antibacterial and the label of virus infection and determiner and its using method
KR101300601B1 (en) * 2011-02-14 2013-08-27 충남대학교산학협력단 Method and Kit for Diagnosing Inflammation and Septicemia
HUE054437T2 (en) * 2011-05-20 2021-09-28 H Lundbeck As Anti-cgrp compositions and use thereof
WO2013083781A2 (en) * 2011-12-08 2013-06-13 Pronota N.V. Biomarkers and test panels useful in systemic inflammatory conditions
EP3367099B1 (en) 2012-02-09 2021-05-26 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2014009480A1 (en) 2012-07-12 2014-01-16 Universität Zürich Method for assaying sepsis and outcome in humans by detection of psp/reg
RU2519729C1 (en) * 2012-10-19 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт общей реаниматологии имени В.А. Неговского" Российской академии медицинских наук Laboratory diagnostic technique for septic encephalopathy in newborns suffering from perinatal hypoxic injury of central nervous system
US10354429B2 (en) 2012-11-14 2019-07-16 Lawrence A. Lynn Patient storm tracker and visualization processor
US9953453B2 (en) 2012-11-14 2018-04-24 Lawrence A. Lynn System for converting biologic particle density data into dynamic images
CN102928606B (en) * 2012-11-16 2015-10-07 武汉明德生物科技股份有限公司 The Procalcitonin quick detection kit of multispecific antibody mark
US20140241602A1 (en) 2013-02-28 2014-08-28 Lawrence A. Lynn System for Presentation of Sequential Blood Laboratory Measurements to Image Recognition Systems
RU2549455C2 (en) * 2013-06-18 2015-04-27 Государственное Бюджетное Учреждение Санкт-Петербургский Научно-Исследовательский Институт Скорой Помощи Им. И.И. Джанелидзе" Method of predicting severe sepsis in patients with acute poisoning by substances with narcotic action
CN103645321A (en) * 2013-12-03 2014-03-19 张超 Test paper for screening procalcitonin and preparation method of test paper
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
CN107076746B (en) 2014-08-14 2020-05-29 米密德诊断学有限公司 Computer analysis of biological data using manifolds and hyperplanes
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
KR101732787B1 (en) 2015-03-16 2017-05-08 대구한의대학교산학협력단 The peptide probes high specific and high selective for target biomarker, and the biochip for clinical prediction of sepsis
CA3000725A1 (en) * 2015-10-06 2017-04-13 Regeneron Pharmaceuticals, Inc. Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
RU169868U1 (en) * 2016-05-04 2017-04-04 Общество С Ограниченной Ответственностью Научно-Производственное Объединение "Биотест" (Ооо Нпо "Биотест") Test system for immunochromatographic determination of procalcitonin in samples of whole blood, serum or plasma for the rapid diagnosis of sepsis
US11340223B2 (en) 2016-07-10 2022-05-24 Memed Diagnostics Ltd. Early diagnosis of infections
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
EP3519833A4 (en) 2016-09-29 2020-06-03 MeMed Diagnostics Ltd. Methods of prognosis and treatment
US11353456B2 (en) 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
EP3502706A1 (en) 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
JP7051096B2 (en) * 2018-05-30 2022-04-11 国立大学法人山口大学 Antibodies that specifically recognize bovine procalcitonin, their antigen-binding fragments, and their use.
JP7205691B2 (en) * 2019-01-23 2023-01-17 ウシオ電機株式会社 Anti-canine procalcitonin antibody and test kit using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0115459A3 (en) * 1983-01-26 1986-11-20 University Of Medicine And Dentistry Of New Jersey Hematological prediction of sepsis and other disease states
US5298605A (en) * 1986-10-08 1994-03-29 Regents Of The University Of Minnesota Antibodies to islet amyloid polypeptide (IAPP) and subunits thereof

Similar Documents

Publication Publication Date Title
RU95108591A (en) METHOD FOR DETERMINING THE STATE OF SEPSIS DISEASE
US6645732B2 (en) Antigen-specific IgG detection
JP3958797B2 (en) Antigen-specific IgM detection
Blaes et al. IgG from “seronegative” myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor
Brickelmaier et al. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-β
US20070134726A1 (en) Diagnostic assay for stroke
JPH059745B2 (en)
US11719697B2 (en) Immunoassay and antibodies for the detection of chromogranin A
WO1998019161A1 (en) Solid phase immunoassay
EP1295127B1 (en) Inter-alpha-trypsin as a marker for sepsis
JPH06502912A (en) Analyte variant analysis
WO2001002853A2 (en) DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY
Johnson Cerebrospinal fluid and blood assays of diagnostic usefulness in multiple sclerosis
Beaulieu et al. The influence of fibronectin on cryoprecipitate formation in rheumatoid arthritis and systemic lupus erythematosus
Thompson¹ et al. Cerebrospinal fluid analysis in the diagnosis of multiple sclerosis
US20090004750A1 (en) Method of Diagnosing Cerebral Infarction
Levinson Kappa/lambda index for confirming urinary free light chain in amyloidosis AL and other plasma cell dyscrasias
JP3522764B2 (en) Assay of free and conjugated trypsinogen-2
CN113447650B (en) Detection kit for anti-peptidyl prolyl cis-trans isomerase D-IgG antibody
CN113447657B (en) Detection kit for detecting anti-aconitate hydratase-IgG antibody
Germani et al. Competitive erythroimmunoassay for detecting Clostridium perfringens type A enterotoxin in stool specimens
CN117917570A (en) Diagnostic kit for determining immune interference substances and application method thereof
CN111323597A (en) Methods, kits and methods of screening compounds for detecting MCI and/or AD in a subject
EP0497901A4 (en)
US20080280305A1 (en) Assays for Detecting Hiv-1 Tat Protein in Hiv-1 Infection